ImmuCell Corp Files 8-K on Security Holder Vote
Ticker: ICCC · Form: 8-K · Filed: Jun 14, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: ICEL
TL;DR
ImmuCell had a shareholder vote on June 13th, details to follow.
AI Summary
On June 13, 2024, ImmuCell Corporation filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific details about the vote itself, such as the proposals or outcomes, but confirms the event occurred.
Why It Matters
This filing signals that ImmuCell Corporation is engaging its shareholders on important corporate matters, which could impact future strategic decisions or governance.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted for a vote by ImmuCell Corporation's security holders?
The provided 8-K filing does not specify the exact proposals or matters that were submitted for a vote by ImmuCell Corporation's security holders.
When did the event related to the submission of matters to a vote of security holders occur?
The earliest event reported in the filing occurred on June 13, 2024.
What is the Commission File Number for ImmuCell Corporation?
The Commission File Number for ImmuCell Corporation is 001-12934.
What is the principal executive office address for ImmuCell Corporation?
The address of ImmuCell Corporation's principal executive offices is 56 Evergreen Drive, Portland, Maine 04103.
What is the IRS Employer Identification Number for ImmuCell Corporation?
The IRS Employer Identification Number for ImmuCell Corporation is 01-0382980.
Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-14 11:33:12
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The Nasdaq
Filing Documents
- ea0207909-8k_immucell.htm (8-K) — 34KB
- 0001213900-24-052706.txt ( ) — 202KB
- iccc-20240613.xsd (EX-101.SCH) — 3KB
- iccc-20240613_lab.xml (EX-101.LAB) — 33KB
- iccc-20240613_pre.xml (EX-101.PRE) — 22KB
- ea0207909-8k_immucell_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders The 2024 Annual Meeting of Stockholders of the Company (the "2024 Annual Meeting") was held by remote communication in the form of both a dial-in conference call and an audio webcast rather than an in-person event on Thursday, June 13, 2024, at 9:30 a.m. Eastern Time, for the following purposes: 1. To elect to one-year terms as Directors of the Company the seven nominees listed in the 2024 Proxy Statement. 2. To approve a non-binding advisory resolution on the Company's
executive compensation program
executive compensation program. 3. To ratify the Audit Committee's selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2024. At the 2024 Annual Meeting, there were present in person or by proxy 6,071,108 shares of the Company's common stock, representing more than 78% of the total outstanding eligible votes. The final voting results for each proposal are as follows: 1. To elect to one-year terms as Directors of the Company the nominees listed in the Company's Proxy Statement dated April 26, 2024: For Withheld Broker Non-votes Gloria J. Basse 3,893,437 528,614 1,649,057 Michael F. Brigham 4,276,766 145,285 1,649,057 Bobbi Jo Brockmann 3,990,836 431,215 1,649,057 Bryan K. Gathagan 3,928,342 493,709 1,649,057 Steven T. Rosgen 3,927,477 494,574 1,649,057 David S. Tomsche 3,926,706 495,345 1,649,057 Paul R. Wainman 3,911,027 511,024 1,649,057 On the basis of this vote, each of the seven nominees was elected to a one-year term as a Director of the Company. 2. To approve a non-binding advisory resolution on the Company's
executive compensation program
executive compensation program: For Against Abstain Broker Non-votes 4,013,133 114,706 294,212 1,649,057 66% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the non-binding advisory resolution on the Company's executive compensation program was approved. 3. To ratify the Audit Committee's selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2024: For Against Abstain Broker Non-votes 6,041,186 10,089 19,833 0 99.5% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the Audit Committee's selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2024 was ratified. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 14, 2024 IMMUCELL CORPORATION By: /s/ Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2